Company news
Edesa Biotech, Inc. (NASDAQ:EDSA) news
Edesa Biotech, Inc. news releases on 6ix. Latest, Mar 22, 2022: Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under…
Press releases — page 2
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 21, 2022
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
February 16, 2022
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
February 13, 2022
Edesa Biotech to Join Ontario Bioscience Panel Discussion
January 25, 2022
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
January 12, 2022
Edesa Biotech Reports Fiscal Year 2021 Results
December 27, 2021
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
November 30, 2021
Edesa Biotech Extends COVID-19 Clinical Study to Poland
November 3, 2021
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
October 18, 2021
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
September 19, 2021
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
September 8, 2021
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
August 25, 2021
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
August 12, 2021
Edesa Biotech Extends Dermatitis Study to Canada
July 12, 2021
Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment
June 22, 2021
Edesa Biotech Reports Favorable Review of COVID-19 Study
June 17, 2021
Edesa Biotech to Attend BIO Digital 2021
June 7, 2021
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
June 2, 2021
Edesa Biotech to Join Panel Discussion at Industry Event
May 27, 2021
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
May 13, 2021
Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome
April 21, 2021
Edesa Biotech Expands Rights to Anti-Inflammatory Technology
March 21, 2021
Edesa Biotech Reaches Enrollment Milestone in COVID Study
March 14, 2021
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
March 8, 2021
Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares
March 1, 2021
Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million
February 24, 2021
Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares
February 24, 2021
Edesa Biotech Reports Fiscal First Quarter 2021 Results
February 15, 2021
Edesa Biotech Receives C$14 million for COVID-19 Study
February 1, 2021
Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
January 25, 2021
Edesa Biotech to Join Panel Discussion at Government COVID-19 Event
January 19, 2021
Edesa Biotech Expands COVID-19 Clinical Study to Colombia
January 10, 2021
Edesa Biotech Issues Letter to Shareholders
December 29, 2020
Edesa Biotech Reports Fiscal Year 2020 Results
December 6, 2020
Edesa Biotech Enrolls First Patient in COVID-19 Study
November 29, 2020
Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference
November 5, 2020
Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study
November 2, 2020
Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.
October 18, 2020
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
August 11, 2020
Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
July 29, 2020
Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study
June 14, 2020
Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results
May 14, 2020
Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
April 19, 2020
Edesa Biotech Reports Fiscal 1st Quarter 2020 Results
February 12, 2020
Edesa Biotech Announces $4.36 million Registered Direct Offering
January 5, 2020
Edesa Biotech Reports Financial Results for Short Period Fiscal Year
December 11, 2019
Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions
December 2, 2019
Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study
October 20, 2019
Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids
September 4, 2019
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study
June 19, 2019